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Methods: To evaluate potential economic benefits of early rule-out of AD, annual medical resource
use and costs for Medicare beneficiaries potentially misdiagnosed with AD prior to their diagnosis of
vascular dementia (VD) or Parkinson’s disease (PD) were compared with that of similar patients
never diagnosed with AD.
Results: Patients with prior AD diagnosis used substantially more medical services every year until
their VD/PD diagnosis, resulting in incremental annual medical costs of approximately $9,500-
$14,000. However, following their corrected diagnosis, medical costs converged with those of pa-
tients never diagnosed with AD.
Discussion: The observed correlation between timing of correct diagnosis and subsequent reversal in
excess costs is strongly suggestive of the role of misdiagnosis of AD - rather than AD comorbidity - in
this patient population. Our findings suggest potential benefits from earlier, accurate diagnosis.
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In 2007, the Aging, Demographics, and Memory Study
estimated that the prevalence of dementia in the United
States among individuals aged 71 years was 13.9% [1].
Alzheimer’s disease (AD) is the most common cause of de-
mentia and accounts for 60%–80% of all dementias in the
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s.org/licenses/by-nc-nd/4.0/).count for up to 20% of all dementia patients [2,3]. Other less
common causes of dementia include frontotemporal
dementias and dementia with Lewy bodies [4]. In addition,
approximately one million Americans have Parkinson’s dis-
ease (PD) [5], which is also associated with dementia [6].
The diagnosis andmanagement of patients with dementing
illnesses can be challenging and uncertain as the underlying
causes can present clinically in ways that mask their true na-
tures or reflect the impact of confounding comorbid condi-
tions [7]. The diagnostic criteria for patients with cognitive
decline rely on a combination of evaluation of cognitive
symptoms, neuropathologic abnormalities, and/or neuroi-
maging techniques that rely on biomarkers to identify factors
indicative of dementia (e.g., dopamine transporter scan for
PD, computed tomography/magnetic resonance imaging for
VD, and amyloid plaques for AD) in the brain [8,9]. The
application of neuropathologic and neuroimaginger’sAssociation. This is anopen access article under theCCBY-NC-ND license
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multiple types of dementia in both clinical and research
settings, even when using strict diagnostic criteria [10–12].
For example, using longitudinal data from the National
Alzheimer’s Coordination Center’s (NACC) research
database, Beach et al. reported that the sensitivity of current
clinical diagnostic criteria for AD ranged from 71% to 87%
and specificity from 44% to 71%, suggesting substantial
rates of AD misdiagnosis among patients with cognitive
impairment [11]. This highlights that although clinical evalu-
ation can reliably detect the presence of cognitive impair-
ment, additional testing may be necessary to accurately
diagnose the cause of the impairment [9].
Prognosis, treatment, and patient management can vary
depending on the underlying cause of dementia. For
example, medications used to treat AD (e.g., acetylcholines-
terase inhibitors) have been found to have limited to no ben-
efits for patients with frontotemporal dementia [13] and VD
[14]. At the same time, previous studies have shown that
early diagnosis and treatment for AD can potentially delay
institutionalization among these patients and result in sub-
stantial cost savings for payers [15,16]. This suggests that
arriving at an accurate and timely diagnosis of dementia is
an important first step for patients, families, physicians,
and policymakers alike.
Although there has been analysis of the economic impli-
cations of timely diagnosis and management for AD, infor-
mation about the implications of potential misdiagnosis of
AD among patients with other dementia etiologies is limited.
For example, a recent study analyzed data from the NACC
Uniform Data Set along with the corresponding NACC
neuropathologic data and found that 18%–67% of the pa-
tients who were misdiagnosed with AD received medica-
tions that were potentially inappropriate [17]. This study,
however, was based on a small sample and did not evaluate
the effects of AD misdiagnosis on medical resource use and
payer costs. Understanding the economic implications of
AD misdiagnosis is especially important given the
increasing prevalence of dementia [2] and the ongoing eval-
uation of the costs and benefits of new technologies that
inform both diagnosis and rule-out of AD among patients
with cognitive decline [18]. The objective of the present
study was to assess potentially avoidable medical service
utilization and the resulting economic benefits of timely
rule-out of AD among USMedicare beneficiaries eventually
diagnosed with VD or PD. Specifically, this study estimated
the excess medical costs among those previously misdiag-
nosed with AD as compared with similar patients with no
history of AD diagnosis.2. Methods
2.1. Data
The study was conducted using deidentified administra-
tive claims data from the Standard Analytical Files for a5% random sample of Medicare beneficiaries. The data
span the period 1999–2011 and include information on ben-
eficiaries’ Medicare enrollment, medical resources used
(e.g., hospitalizations, emergency room [ER] visits), and
associated payments made by Medicare to providers. The
data do not include Medicare Part D claims—i.e., prescrip-
tion drug information was not available for analysis.2.2. Study sample and time periods
Twomutually exclusive cohorts of patients with eitherVD
or PD diagnoses (International Classification of Disease,
Ninth Revision, Clinical Modification [ICD-9-CM]) were
identified in theMedicare database. Given the potential over-
lap in the presentation of various dementia types, it was
important to differentiate between patients with potential
misdiagnoses that were later reconciled to be either VD or
PD from those with comorbid dementias. Although the
claims data do not contain clinical metrics to directly assess
such a difference, the sequence of medical claims and diag-
noses over time can shed light on clinicians’ evaluation of a
patient’s condition. For example,multiple intertwined claims
for medical services over time with diagnoses for different
causes of dementia could possibly point to patients with co-
morbid or mixed dementia. Conversely, a pattern of consec-
utive diagnoses for a specific cause of dementia, with no
intervening or superseding claims with diagnoses of other
causes of dementia, is suggestive of a stable, single diagnosis.
This stable, correct diagnosis may come well after an earlier
episode of care associated with other suspected causes of de-
mentia. Therefore, to be included in the analysis, patients
were required to have at least two claims with diagnoses of
VD or PD, with no other dementia diagnoses (including
AD) between or after them. The first of the two consecutive
diagnoses that met these criteria was defined as the
“confirmed diagnosis” of VD/PD.
Because the primary aim was to study the differences in
medical resource use and costs for patients who were previ-
ously misdiagnosed with AD, we separated the patients into
twogroupswithineachcohort basedon thehistoryofADdiag-
nosis before the confirmed VD/PD diagnosis. Patients were
considered to be misdiagnosed with AD if they had at least
two claims with an AD diagnosis code, with their first AD
diagnosis within 3 years before their confirmed VD/PD diag-
nosis. As noted previously, such sequencing of claims (multi-
ple AD diagnoses strictly followed by multiple diagnoses of
VD or PD) was chosen to increase the likelihood that patients
were indeed misdiagnosed with AD, rather than have comor-
bid AD and either VD or PD. Patients with single AD diag-
nosis, or intertwined diagnoses, were excluded. Patients with
no AD diagnosis at any point before or after their confirmed
VD/PD diagnosis were considered as potential comparators.
The index date was defined as the date of the first AD
diagnosis for patients with prior AD diagnosis and as the
date of the first confirmed diagnosis of VD or PD for the po-
tential controls. These index dates were assumed to reflect
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related to either AD or VD/PD. To identify any observable
differences between the two cohorts before they presented
with dementia-like symptoms, patient characteristics
including demographics, comorbidity profile (i.e., the Charl-
son comorbidity index [CCI] and its components) [19], and
medical services used were evaluated in the 6-month period
before the index date (“baseline”). Characteristics were
compared across the two cohorts using chi-squared tests
for categorical variables and Wilcoxon rank-sum tests for
continuous variables. Patients were followed for up to 4
years post index, allowing a follow up of at least 12 months
after the confirmed VD/PD diagnosis (Fig. 1).2.3. Outcomes and analytical approach
We examined annual incremental costs (i.e., payments by
Medicare to providers) for medical services used by VD/PD
patients previously misdiagnosed as having AD relative to
similar patients who were correctly diagnosed with VD/PD
from the onset. Excess medical costs (i.e., difference in costs
between misdiagnosed patients and similar correctly diag-
nosed patients, in 2012 US dollars) were examined over
time, in 1 year increments starting from the index date,
both leading up to and following the confirmed VD/PD diag-
nosis. In addition to overall medical costs, the components of
the total medical cost differential in terms of both utilization
and costs associated with various types of medical services
used (e.g., hospitalizations, ER visits) were evaluated. The
analyses were conducted separately for patients with VD
and those with PD.
Our analytical approach consisted of two parts: first, pa-
tients with a history of misdiagnosis were matched to
comparator patients with similar characteristics before the
index date using propensity score matching to account for
potential confounding factors. Then, medical resource use
and costs over time were compared between matched pa-Fig. 1. Patient selection, study timeline, and comparison cohorts. A total of 259,2
excluded because they had1 diagnosis for dementia types other than VD/PD (e.g.
diagnoses. Additional 13,858 patients with 1 AD diagnoses were excluded becau
VD/PD diagnosis. Of the remaining patients, 60,706 did not have continuous insura
fore excluded. Abbreviations: VD, vascular dementia; PD, Parkinson’s disease; Atients with and without prior AD diagnosis. Because match-
ing can result in the exclusion of a subset of patients,
potentially affecting the generalizability of the findings, a
sensitivity analysis was conducted using multivariate
models (see Section 2.4 for details).
Propensity scores were estimated using logistic regres-
sion models with group assignment as the dependent vari-
able and all the baseline characteristics as independent
variables. The two groups were then matched 1:1 using a
propensity score-based “greedy” matching method [20,21].
Specifically, each patient with prior AD was matched to a
potential control whose propensity score differed from his
own by a distance 0.25 of the standard deviation of the
propensity score across all patients. Potential controls were
also required to have identical index years and length of
follow-up (relative to index quarter) as their matched coun-
terparts. After matching, patient characteristics were re-
evaluated using McNemar’s tests for categorical variables
and Wilcoxon signed-rank tests for continuous variables to
ascertain whether statistical differences remained between
the matched pairs.
Next, annual frequency of medical services used (overall
and by type—e.g., hospitalizations, outpatient/physician
visits) and associated costs during the follow-up period
were compared between matched pairs in 1-year intervals,
stratified by time from index date to first confirmed VD/
PD diagnosis. Statistical comparisons of differences in
mean annual costs were conducted using nonparametric
bootstrap methods [22].2.4. Sensitivity analysis
Regression-adjusted annual medical costs were
compared between those with and without prior AD diag-
nosis among VD/PD patients using generalized linear
regression models with a log link and a gamma distribution
of the error term. The dependent variable was annual costs,61 patients had 1 VD/PD diagnosis in 1999–2011. Of these, 138,335 were
, frontotemporal dementia, AD) between or after the twomost recent VD/PD
se their first 2 AD diagnoses were not within 3 years before their confirmed
nce coverage (eligibility) throughout the observation period and were there-
D, Alzheimer’s disease.
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The models accounted for the same set of baseline patient
characteristics that were included in the propensity score
matching analysis.3. Results
3.1. Sample characteristics
Approximately one in six (17%) of the 15,367 VD pa-
tients in our study was classified as misdiagnosed with AD
before their confirmed VD diagnosis. Similarly, about one
in 12 (8%) of the 30,995 PD patients analyzed had a history
of AD misdiagnosis. Among the misdiagnosed patients
included in the study, median time to confirmed VD/PD
diagnosis was approximately four quarters (Fig. 2).
Before matching, VD/PD patients previously misdiag-
nosed with AD were significantly older and more likely to
be female relative to those with no prior misdiagnosis. In
addition, patients eventually diagnosed with PD had a higher
CCI and were more likely to use medical services (i.e., have
ER visits, outpatient/physician office visits, inpatient stays
and so forth) at baseline, compared with those not previously
misdiagnosed (Table 1).
Baseline differences were largely eliminated following
propensity score matching (Table 1). The matched samples
consisted of 2088 and 2058 matched pairs of VD and PD pa-
tients, respectively, reflecting approximately 80% of the
misdiagnosed patients in each group.Fig. 2. Time from index date to first confirmed diagnosis among patients previous
as the date of the first AD diagnosis.3.2. Differences in total health care costs
Despite having similar characteristics before their index
dates, patients with prior AD diagnosis incurred significantly
higher medical costs in the periods leading up to and
including their confirmed diagnosis, compared with patients
without prior AD diagnosis (Figs. 3 and 4).
Specifically, examining separately patients correctly
diagnosed within 1, 2, or 3 years after AD misdiagnosis
shows that correct diagnosis was consistently associated
with a reversal in the excess costs trend. Although costs
among the misdiagnosed patients were higher and usually
increasing leading up to and including the year of correct
diagnosis, the differences largely dissipated in subsequent
years, with misdiagnosed patients’ costs converging to those
with no prior misdiagnosis (Figs. 3 and 4). Over time, excess
medical costs for patients with prior AD diagnosis peaked at
approximately $9500 to .$14,000 per patient per year,
depending on the time to confirmed VD/PD diagnosis.
Further analysis found that approximately two-thirds of
the excess costs in the year of confirmed VD/PD diagnosis
were incurred in the quarter of confirmed diagnosis alone
(see Supplementary Table 1 for details).3.3. Differences in frequency and costs of medical services
used
To better understand the main drivers of excess medical
costs in the year of confirmed diagnosis among patients mis-
diagnosed with AD, the utilization and costs of differently misdiagnosed with Alzheimer’s disease (AD). The index date was defined
Table 1
Characteristics of vascular dementia (VD) and Parkinson’s disease (PD) patients—during 6 months before the index date*
Characteristics
Prematch Postmatch
Prior ADy No prior AD Pz Prior ADy No prior AD Px
Vascular dementia (VD), n 2544 12,823 N/A 2088 2088 N/A
Demographics
Age{, mean (SD) 80.5 (8.1) 78.4 (10.5) ,.001 80.6 (8.0) 80.0 (9.7) .107
Male, % 33 38 ,.001 34 32 .247
CCI, mean (SD) 2.2 (2.0) 2.3 (2.1) .034 1.9 (1.9) 1.9 (1.9) .722
Select medical resource use, % with 1 visit
Emergency room 43 43 .632 41 41 .974
Inpatient 29 32 .001 27 26 .525
Outpatient/physician 95 95 .443 94 94 .832
Laboratory 84 86 .026 83 83 1.000
Other# 68 69 .135 65 65 .945
Parkinson’s disease (PD), n 2604 28,391 N/A 2058 2058 N/A
Demographics
Age{, mean (SD) 78.6 (7.7) 74.6 (10.1) ,.001 78.6 (7.8) 78.9 (8.2) .035
Male, % 45 51 ,.001 45 46 .778
CCI, mean (SD) 1.7 (1.8) 1.5 (1.8) ,.001 1.7 (1.8) 1.6 (1.7) .134
Select medical resource use, % with 1 visit
Emergency room 40 29 ,.001 38 37 .269
Inpatient 27 19 ,.001 25 25 .561
Outpatient/physician 98 95 ,.001 97 97 .838
Laboratory 86 83 ,.001 86 86 .613
Other# 71 63 ,.001 70 68 .140
Abbreviations: AD, Alzheimer’s disease; N/A, not applicable; SD, standard deviation; CCI, Charlson comorbidity index.
*The index date was defined as the date of the first AD diagnosis for those with prior AD misdiagnosis and as the earliest date with a VD/PD diagnosis after
which no diagnoses for a non-VD/PD dementia occurred for those with no prior AD misdiagnosis.
yPrior AD misdiagnosis was defined as 2 diagnoses for AD within the three years preceding the first confirmed VD/PD diagnosis.
zChi-squared tests were used to compare categorical variables and Wilcoxon rank-sum tests were used for age and CCI.
xMcNemar’s tests were used to compare categorical variables and Wilcoxon signed-rank tests were used for age and CCI.
{Age was calculated on the index date.
#Other types of resource use include home health care, care received in skilled nursing facilities, use of durable equipment and imaging services, and places of
services not clearly classified in select medical resource use categories (e.g., specialist visits, rehabilitation centers).
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compared with those of matched patients correctly diag-
nosed from the onset. As seen in Table 2, depending on
the year of confirmed diagnosis, VD patients who were pre-
viously misdiagnosed had, on average, 40%–143% more
inpatient days, 45%–79% more ER visits, 19%–48% more
outpatient/physician visits, 61%–221%more skilled nursing
facility visits, 13%–56% more home health care days, and
up to 44% more claims for durable medical equipment per
year, compared with matched controls.
Fig. 5 reports the share of excess costs associated with the
main categories of resource use during the same periods.
Among VD patients, the key driver of the excess cost differ-
ential in the year of confirmed diagnosis was greater cost of
hospitalizations, which accounted for 36%–44% of the incre-
mental costs. Of note, for both groups (i.e., VD patients with
and without prior misdiagnosis), a substantial share of inpa-
tient stays in the year of confirmed diagnosis (64%–74%) re-
sulted from ER visits. Other cost drivers included higher
costs of care in skilled nursing facilities (33%–42%) and in
outpatient facilities or physician offices (8%–12%).
Similar resource use and cost results were observed for
previously misdiagnosed PD patients (Table 2 and Fig. 5).3.4. Sensitivity analysis
Using regression-adjusted means based on the multivar-
iate analysis resulted in similar findings for the costs strati-
fied by time to correct diagnosis (see Supplementary Figs.
1 and 2, available online, for results).4. Discussion
The results of this study suggest substantial levels of
AD misdiagnosis among Medicare beneficiaries who
eventually receive a corrected diagnosis of either VD or
PD (17% and 8%, respectively). These findings are
consistent with previous studies as well as expert testi-
mony presented at a Medicare Evidence Development
and Coverage Advisory Committee meeting, noting AD
misdiagnosis rates ranging from 12% to 23% in patholog-
ically confirmed studies [23]. Our research provides
further insight into this problem: for half of the misdiag-
nosed patients, a correct diagnosis may not be confirmed
for over 1 year, leaving patients subject to extended
periods of potentially inappropriate treatment. These pe-
riods coincide with substantially higher levels of medical
Fig. 4. Excess annual medical costs among Parkinson’s disease (PD) patients previously misdiagnosed with Alzheimer’s disease (AD)—by time from index
date to first confirmed PD diagnosis. Excess medical costs (paid to providers by Medicare) were calculated as the difference in costs between patients with prior
AD and those with no prior AD. Statistical significance evaluated using paired t tests with bias-corrected bootstrapping.
Fig. 3. Excess annual medical costs among vascular dementia (VD) patients previously misdiagnosed with Alzheimer’s disease (AD)—by time from index date
to first confirmed VD diagnosis. Excess medical costs (paid to providers by Medicare) were calculated as the difference in costs between patients with prior AD
and those with no prior AD. Statistical significance evaluated using paired t tests with bias-corrected bootstrapping.
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Table 2
Medical resource use among patients previously misdiagnosed with Alzheimer’s disease (AD) and their matched counterparts—in the year of confirmed
diagnosis
Characteristics
Time of confirmed diagnosis relative to index date
Year 1 Year 2 Year 3
Prior AD* No prior AD Py Prior AD* No prior AD Py Prior AD* No prior AD Py
Vascular dementia (VD), n 1005 637 446
Average (mean) number of
Inpatient days 14.43 10.27 ,.001 6.77 2.93 ,.001 6.48 2.67 ,.001
Emergency room visits 6.63 4.57 ,.001 4.22 2.56 ,.001 4.07 2.27 ,.001
Outpatient/physician office visits 42.45 35.79 ,.001 35.12 23.70 ,.001 32.32 22.85 ,.001
Home health care days 1.21 1.07 .135 0.77 0.50 .001 0.74 0.51 .004
Skilled nursing facility days 35.73 22.14 ,.001 18.81 5.86 ,.001 18.47 6.03 ,.001
Laboratory visits 16.14 15.42 .029 15.66 13.11 ,.001 13.95 11.90 .001
DME claims 4.33 4.03 .462 3.04 3.08 .665 3.85 2.68 .014
Other visitsz 7.31 5.66 ,.001 5.24 3.16 ,.001 4.72 3.16 ,.001
Parkinson’s disease (PD), n 1089 588 381
Average (mean) number of
Inpatient days 10.34 7.03 ,.001 6.65 3.11 ,.001 6.73 3.08 ,.001
Emergency room visits 5.30 4.45 ,.001 4.21 2.39 ,.001 4.60 2.20 ,.001
Outpatient/physician office visits 40.56 33.75 ,.001 33.64 24.72 ,.001 34.61 25.47 ,.001
Home health care days 1.46 1.11 ,.001 1.23 0.87 .001 1.10 0.76 .003
Skilled nursing facility days 22.40 16.00 ,.001 13.93 6.45 ,.001 16.35 4.81 ,.001
Laboratory visits 14.63 13.17 ,.001 13.68 11.54 .001 14.27 10.73 ,.001
DME claims 5.49 4.79 .001 4.89 4.37 .202 4.86 3.13 .020
Other visitsz 6.74 5.17 ,.001 5.19 3.66 ,.001 5.55 3.39 ,.001
Abbreviation: DME, durable medical equipment.
*Prior AD misdiagnosis was defined as 2 diagnoses for AD within the 3 years preceding the first confirmed VD/PD diagnosis.
yAbsolute differences in annual resource use were compared using Wilcoxon signed-rank tests.
zOther types of resource use include places of services not clearly classified in select medical resource use categories (e.g., specialist visits, rehabilitation
centers).
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patients are ultimately correctly diagnosed.
The demonstration that substantial and potentially avoid-
able medical services and related costs immediately dissi-
pate after a correct non-AD diagnosis is a key finding for
understanding the role that early and accurate diagnosis
can play in effective management of Medicare beneficiaries
with dementia. These results are consistent with those of
previous studies that have found that arriving at a correct
diagnosis can reduce the use of unnecessary resources
[24,25]. For example, in a clinical trial, Grundman et al.
found that after confirming the dementia etiology
using amyloid imaging results, physicians often did not
order additional brain imaging or neuropsychological
testing but altered the treatment regimens depending on
whether the patient had AD [25]. Our finding takes on added
importance given that the trends in resource use and costs
remain similar regardless of whether patients received a cor-
rect diagnosis in the first, second, or third year after their AD
misdiagnosis, thereby suggesting that greater patient benefit
and cost saving could be achieved via early and accurate
diagnosis.
Fig. 5 enumerates the costs associated with excess use of
specific medical services among patients previously mis-
diagnosed with AD. It is noteworthy that many of the service
types driving the excess costs, increased days spent in the
hospital and skilled nursing facilities, additional visits tothe ER, and so forth, are typically indicative of worse patient
outcomes. The elevated rates of these negative patient
outcome surrogates suggest that the impact of a misdiag-
nosis may extend beyond simply requiring additional tests
to provide more information or spending more time with a
primary care physician as additional health factors are
considered. The fact that this type of excess medical service
use disappears once a correct diagnosis is achieved provides
further evidence of the relationship between accurate diag-
nosis and improved patient outcomes.
Given the overlap in presentations of potentially unclear
dementia causes, it is tempting to try to explain these find-
ings as an unavoidable aspect of the difficulty in differential
diagnosis—excess costs attributed not to misdiagnosis but
rather to the treatment of comorbid conditions, including
multiple dementia types. Although both clinical and coding
realities make this possible, the methods used in this analysis
suggest an alternative explanation for the findings. The extra
care taken in the selection of the study sample to remove pa-
tients with patterns clearly suggestive of comorbid dementia,
and the strong correlation found between the timing of cor-
rect diagnosis and subsequent reversals in peak excess costs,
are strongly suggestive of the role of misdiagnosis of AD in
this patient population. Furthermore, by examining poten-
tially avoidable medical services and their costs compared
with a matched sample of similar Medicare patients, we
have minimized most observed differences between the
Fig. 5. Components of excess medical costs in the year of confirmed diagnosis—by time of confirmed diagnosis relative to index date. Excess medical costs
were calculated as the difference in costs of patients with prior AD and those without prior AD. Annual medical costs were compared using paired t tests with
bias-corrected bootstrapping. Inpatient costs include ER visits resulting in an inpatient admission; outpatient/physician costs include doctor visits, ER visits not
resulting in an inpatient admission, and laboratory and imaging services used in an outpatient setting or doctor’s office; other visits include durable medical
equipment use and places not classified as inpatient, outpatient/physician, skilled nursing facility, or home health care. Abbreviations: AD, Alzheimer’s disease;
ER, emergency room.
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nosis as the most notable difference between the groups. As a
result, the attribution of our findings is less likely to align
with the challenges of real-world medical practice and
more likely to be attributable to the accuracy and timeliness
of a patient’s dementia diagnosis.4.1. Study limitations
First, the analyses relied on information captured within
the Medicare administrative claims data set, and the effects
of any inaccuracies in the data elements on the study findings
are unknown. Furthermore, the ICD-9 CM codes used to
identify the study population are retrieved from billing
claims records and do not contain any information by which
to confirm clinical diagnoses, severity of illness, or physician
interpretation. Additionally, previous research has demon-
strated substantial rates of potentially inappropriate medica-
tion use among patients misdiagnosed as having AD.
However, these claims records do not include prescription
drug use and over-the-counter medications. As such, the im-
plications of ADmisdiagnosis on the treatment of patients in
our sample are unknown. Effects onmedical services covered
wholly or in part by other payers, out of pocket expenses, and
informal care are also not captured within this framework.
Second, the propensity score matching approach effec-
tively controls for observed differences within the data set
but cannot address any unobserved patient characteristics.Third, although the study findings demonstrate that
misdiagnosis of AD is associated with excess health care
resource use and costs relative to those correctly diagnosed
from the onset, specific mechanisms resulting in these differ-
ential estimates need to be further explored in the future.
Finally, the study findings are limited to beneficiaries
enrolled in the traditional fee-for-service Medicare program,
and additional research is required to understand whether
similar patterns are observed among those enrolled in Medi-
care Advantage (managed care) plans.5. Conclusions
The significant and potentially avoidable medical
resource use and related costs associated with misdiagnosis
of AD—and their dissipation after the correction of that diag-
nosis—suggest substantial value not only of ruling out AD
but of doing so as early as possible. The ability to limit inpa-
tient hospital stays, minimize ER visits, and potentially avoid
additional medical procedures and interactions adds clarity
and understanding to the role that timely and accurate de-
mentia diagnoses can play in patients’ lives while potentially
providing substantial savings within the Medicare system.Acknowledgments
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1. Systematic review: A review of recent literature sug-
gests considerable challenges in differential diag-
nosis of underlying causes of dementia among
patients with cognitive impairment, potentially
affecting their clinical management. Although prior
research has considered the implications of earlier
diagnosis and treatment of Alzheimer’s disease
(AD), the effects of misdiagnosis of AD among pa-
tients with other dementia etiologies have remained
largely unexplored.
2. Interpretation: We find substantial excess medical
resource use and costs associated with misdiagnosis
of AD among Medicare beneficiaries. The ability to
limit medical resource use and potentially avoid
additional medical procedures and interactions help
clarify the role that timely and accurate dementia di-
agnoses can play in patients’ lives, while potentially
providing substantial savings within the Medicare
system.
3. Future directions: Future research is necessary to
explore the specific mechanisms through which
misdiagnosis of AD increases medical resource use
and costs and to assess the degree to which they are
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